Post Herpetic Neuralgia (PHN)
Conditions
Keywords
Post-Herpetic Neuralgia, Neuropathic Pain, Herpes Zoster, Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Non-invasive Neuromodulation, Chronic Pain Management, Pain Relief, Randomized Controlled Trial
Brief summary
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.
Detailed description
Post-herpetic neuralgia (PHN) is a chronic neuropathic pain condition that persists for months or years following the resolution of herpes zoster (HZ) infection. It is characterized by persistent burning, stabbing, or shooting pain, often accompanied by allodynia and hyperalgesia, which can significantly impair quality of life. Current treatment options for PHN, including pharmacological therapies, often provide incomplete pain relief and are associated with side effects, creating a need for novel, non-invasive interventions. This randomized controlled trial aims to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) as an adjunct to standard medical treatment for patients with PHN. The vagus nerve plays a crucial role in modulating pain perception and inflammatory processes, and its non-invasive stimulation through the auricular branch has shown promising analgesic effects in various chronic pain syndromes. A total of 34 male and female participants, aged 35-65 years, diagnosed with PHN will be randomly allocated into two equal groups (17 participants per group). Group A (Experimental) will receive taVNS in addition to conventional pharmacological management, while Group B (Control) will receive conventional pharmacological management alone. The taVNS intervention will be delivered using the EV-906 device with TENS ear clips, applied according to the study protocol and safety standards (ISO 13485, FDA QSR, and CE compliance). Pain intensity and quality will be assessed at baseline, after two weeks, and after four weeks using validated outcome measures: the Brief Pain Inventory (BPI) short form and the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2). The primary outcome is the change in pain severity scores, and the secondary outcome is the change in pain interference with daily activities. The results of this study will provide evidence regarding the clinical utility of taVNS as a safe, non-invasive, and effective adjunct therapy for PHN, with the potential to improve patient outcomes and quality of life
Interventions
Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards
OTHERtraditional medical treatment for PHN
Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.
Sponsors
Mohamed Hosny Ismail Easa
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Thirty-four male and female patients diagnosed with PHN, aged between 35 and 65 years, will be randomly allocated into two equal groups, each containing 17 patients: Group (A): Study group - This group will receive taVNS in addition to traditional medical treatment. Group (B): Control group - This group will receive the same traditional medical treatment only.
Eligibility
Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Adults aged 35-65 years diagnosed with PHN. Persistent pain for at least 3 months after herpes zoster infection. Only patients who sign the informed consent form will be included.
Exclusion criteria
Contraindications to taVNS such as: 1. pregnancy; 2. active implants (e.g., pacemakers, cochlear implants) or brain shunts; 3. previous neurological or psychiatric diagnoses; 4. history of addiction or substance abuse; 5. history of trauma and/or brain surgery; 6. cardiac disease; 7. acute or chronic use of medications and/or illicit drugs; 8. susceptibility to headaches and seizures. Severe cognitive impairment. Other chronic pain conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brief Pain Inventory - Short Form (BPI-SF) | Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based. | the Brief Pain Inventory-Short Form (BPI SF) is a valuable tool for assessing pain severity and its impact on daily functioning on a 0-10 numeric rating scale, with higher scores indicating more severe pain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Short form McGill pain questionnaire 2 (SF-MPQ-2) | Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based. | The SF-MPQ-2 is a validated tool assessing sensory, affective, and evaluative qualities of pain. Participants rate the intensity of their pain using a 0-10 scale: 0: No pain 10: Worst pain imaginable Participants select the rating that best reflects their experience during the past week. |
Countries
Egypt
Contacts
CONTACTMohamed Hosny Ismail Easa, MSc, PT
STUDY_CHAIRWafaa Hussein Borhan, PhD
Professor of Physical Therapy for Surgery Department, Faculty of Physical Therapy, Cairo University
STUDY_DIRECTORRofaida El Sayed El Naggar, MD
Lecturer of Dermatology, Kasr Alainy, Faculty of Medicine, Cairo University
STUDY_DIRECTORDoaa Atef Aly, PhD
Lecturer of Physical Therapy for Surgery Department, Faculty of Physical Therapy, Cairo University
Outcome results
None listed